12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tysabri natalizumab: Preliminary postmarketing study data

Preliminary data from the open-label, international postmarketing Tysabri observational program (TOP) in 3,484 patients with relapsing-remitting MS (RRMS) showed that Tysabri significantly reduced ARR at 4 years to 0.28 from 1.99 at baseline (p<0.0001), while disability as measured by Expanded Disability...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >